Table 1.
Participant characteristics, by treatment
| Total | No systemic therapy | Standard systemic therapy | Targeted therapy | P‐value | Missing | |
| Total, n | 3720 | 2299 | 497 | 924 | ||
| Shielded, n (%)a | 2262 (60·8) | 1360 (59·2) | 292 (58·8%) | 610 (66·0%) | < 0·001 | 0 |
| Advised to shield, n (%), UK only | 1092 (42·4%) | 523 (31·6%) | 164 (51·4%) | 405 (67·2%) | < 0·001 | 4 |
| UK resident, n (%) | 2578 (69·4%) | 1656 (72·1%) | 319 (64·6%) | 603 (65·2%) | < 0·001 | 7 |
| Male sex, n (%) | 1174 (31·6%) | 632 (27·5%) | 158 (31·8%) | 384 (41·6%) | < 0·001 | 2 |
| Age in years, mean (SD) | 49·2 (15·0) | 49·3 (15·7) | 49·0 (14·8) | 49·0 (13·2) | 0·84 | 25 |
| Ethnicity, n (%) | < 0·001 | 0 | ||||
| White ethnicity | 2990 (80·4%) | 1856 (80·7%) | 386 (77·7%) | 748 (81·0%) | ||
| Hispanic or Latino | 158 (4·2%) | 95 (4·1%) | 29 (5·8%) | 34 (3·7%) | ||
| South Asian | 127 (3·4%) | 69 (3·0%) | 23 (4·6%) | 35 (3·8%) | ||
| Japanese | 90 (2·4%) | 29 (1·3%) | 18 (3·6%) | 43 (4·7%) | ||
| Black African/Caribbean/American | 86 (2·3%) | 68 (3·0%) | 6 (1·2%) | 12 (1·3%) | ||
| Other | 269 (7·2%) | 182 (7·9%) | 35 (7·0%) | 52 (5·6%) | ||
| Body mass index, mean (SD) | 27·4 (6·1) | 26·8 (5·8) | 27·7 (6·0) | 28·8 (6·5) | < 0·001 | 301 |
| Alcohol > 14 units a week, n (%) | 484 (13·6%) | 291 (13·4%) | 57 (12·0%) | 136 (15·1%) | 0·24 | 168 |
| Current smoker, n (%) | 460 (13·1%) | 259 (12·1%) | 69 (14·6%) | 132 (14·8%) | 0·076 | 207 |
| Full‐time employment, n (%) | 1664 (44·7%) | 951 (41·4%) | 223 (44·9%) | 490 (53·0%) | < 0·001 | 0 |
| Number in household, mean (SD) | 2·7 (1·7) | 2·7 (1·6) | 2·9 (1·8) | 2·7 (1·8) | 0·19 | 9 |
| Key worker, n (%) | 985 (26·6%) | 585 (25·6%) | 146 (29·4%) | 254 (27·6%) | 0·16 | 15 |
| Diagnosis, n (%) | < 0·001 | 54 | ||||
| Psoriasis | 2869 (78·3%) | 1539 (68·6%) | 462 (93·0%) | 868 (93·9%) | ||
| Inflammatory arthritisb | 529 (14·4%) | 465 (20·7%) | 23 (4·6%) | 41 (4·4%) | ||
| Connective tissue disease | 127 (3·5%) | 113 (5·0%) | 9 (1·8%) | 5 (0·5%) | ||
| Axial spondyloarthritis | 85 (2·3%) | 75 (3·3%) | 1 (0·2%) | 9 (1·0%) | ||
| Other | 56 (1·5%) | 53 (2·4%) | 2 (0·4%) | 1 (0·1%) | ||
| COVID‐19 diagnosis, n (%) | 257 (7·1%) | 131 (5·8%) | 46 (9·7%) | 80 (9·0%) | < 0·001 | 111 |
| One or more comorbidity, n (%) | 1651 (44·4%) | 949 (41·3%) | 224 (45·1%) | 478 (51·7%) | < 0·001 | 0 |
| Anxiety, n (%) | 958 (27·2%) | 605 (28·1%) | 138 (29·2%) | 215 (23·9%) | 0·032 | 197 |
| Depression, n (%) | 925 (26·2%) | 593 (27·5%) | 127 (26·9%) | 205 (22·8%) | 0·024 | 196 |
aShielded refers to participants who quarantined and self‐isolated; binflammatory arthritis included any participant with a diagnosis of rheumatoid arthritis or psoriatic arthritis.